US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Brookfield Real Assets Income Fund Inc.

13.11

-0.0050-0.04%

Volume:148.01K

Turnover:1.94M

Market Cap:724.45M

PE:-8.09

High:13.14

Open:13.12

Low:13.10

Close:13.11

Loading ...

Overview Company News Filings

Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?

AgEagle Aerial Systems Participated in the French Army’s 61st Artillery Regiment Event FID25-61e RA Chaumont

Brookfield Real Assets Income Fund Inc. Announces Quarterly Webcast

Regional SA de Cv (MEX:RA) Q4 2024 Earnings Call Highlights: Strong Loan Growth and Strategic ...

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

CPF closes Special Accounts for members aged 55 years and above

Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts

Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Press Release: RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases

Brookfield Real Assets Income Fund Inc. Declares Q1 2025 Distribution Schedule

Press Release: RA Capital Management Announces Close of $1.4 Billion Acquisition of Aliada Therapeutics by AbbVie

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates

Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024

Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/RA/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"RA"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","market":"US","secType":"STK","nameCN":"Brookfield Real Assets Income Fund Inc.","latestPrice":13.105,"timestamp":1742323843279,"preClose":13.11,"halted":0,"volume":148007,"delay":0,"changeRate":-0.000381,"change":-0.005,"floatShares":55280700,"shares":55280700,"eps":-1.61933,"lyrEps":0,"amount":1939972.1511000001,"amplitude":0.003295,"volumeRatio":0.812414,"dividePrice":1.416,"prevYearClose":13.32,"fiveDayClose":13.23,"twentyDayClose":13.39},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RA\",,,,,undefined,":{"symbol":"RA","floatShares":55280700,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.812414,"shares":55280700,"dividePrice":1.416,"high":13.14,"amplitude":0.003295,"preClose":13.11,"low":13.0968,"week52Low":12.165,"pbRate":"--","week52High":13.77,"institutionHeld":0,"latestPrice":13.105,"committee":0.415385,"eps":-1.61933,"divideRate":0.10805,"volume":148007,"delay":0,"ttmEps":-1.61933,"open":13.12,"prevYearClose":13.32,"prevWeekClose":13.11,"prevMonthClose":13.35,"prevQuarterClose":13.32,"fiveDayClose":13.23,"twentyDayClose":13.39,"sixtyDayClose":13.22},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RA\",params:#limit:5,,,undefined,":[{"date":"2025-03-13","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-13","defaultRemindTime":1741872600000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-27","payableDate":"2025-03-13","currency":"USD","dateTimestamp":1741838400000,"payDate":"2025-03-27"},{"date":"2025-02-06","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-06","defaultRemindTime":1738852200000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-20","payableDate":"2025-02-06","currency":"USD","dateTimestamp":1738818000000,"payDate":"2025-02-20"},{"date":"2025-01-10","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-09","defaultRemindTime":1736519400000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-23","payableDate":"2025-01-09","currency":"USD","dateTimestamp":1736485200000,"payDate":"2025-01-23"},{"date":"2025-01-09","symbol":"RA","amount":0.118,"announcedDate":"2024-12-27","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-09","defaultRemindTime":1736433000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-01-23","payableDate":"2025-01-09","currency":"USD","dateTimestamp":1736398800000,"payDate":"2025-01-23"},{"date":"2024-12-10","symbol":"RA","amount":0.118,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-10","defaultRemindTime":1733841000000,"name":"Brookfield Real Assets Income Fund Inc.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-10","currency":"USD","dateTimestamp":1733806800000,"payDate":"2024-12-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RA\",market:\"US\",,,undefined,":[{"executeDate":"2016-12-13","recordDate":"2016-12-15","paymentDate":"2016-12-22","value":0.199,"currency":"USD"},{"executeDate":"2017-03-14","recordDate":"2017-03-16","paymentDate":"2017-03-23","value":0.199,"currency":"USD"},{"executeDate":"2017-04-18","recordDate":"2017-04-20","paymentDate":"2017-04-27","value":0.199,"currency":"USD"},{"executeDate":"2017-05-16","recordDate":"2017-05-18","paymentDate":"2017-05-25","value":0.199,"currency":"USD"},{"executeDate":"2017-06-13","recordDate":"2017-06-15","paymentDate":"2017-06-22","value":0.199,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RA\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RA\",pageSize:16,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2509552283","title":"Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2509552283","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509552283?lang=en_us&edition=fundamental","pubTime":"2025-02-05 19:38","pubTimestamp":1738755480,"startTime":"0","endTime":"0","summary":"Exagen Inc.  shares soared 29.4% in the last trading session to close at $5.02. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 14.5% gain over the past four weeks.The recent surge in Exagen shares can be attributed to the ongoing positive trend that the company is witnessing post its announcement of a solid fourth quarter and full year 2024 preliminary results in January. XGN also received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus  and rheumatoid arthritis  biomarker assays. Also, XGN is witnessing a positive earnings estimate revision as loss estimate for 2025 improved from 70 cents to 58 cents in the past 30 days. As a result, investors are anticipating continued growth in earnings and revenue, which is expected to drive the stock’s upward momentum in the coming quarters.This company is expected to post quarterly loss of $0.27 per share in i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-exagen-xgn-29-113800709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RA","CAPR","BK4139","SLE","BK4077","XGN"],"gpt_icon":0},{"id":"2508454667","title":"AgEagle Aerial Systems Participated in the French Army’s 61st Artillery Regiment Event FID25-61e RA Chaumont","url":"https://stock-news.laohu8.com/highlight/detail?id=2508454667","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508454667?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:54","pubTimestamp":1738677240,"startTime":"0","endTime":"0","summary":"Key drone innovation forum for the French Army features eBee VISION flight demonstration WICHITA, Kan., Feb.  04, 2025  (GLOBE NEWSWIRE) -- AgEagle Aerial Systems Inc. (NYSE: UAVS)a leading provider o","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/04/3020365/0/en/AgEagle-Aerial-Systems-Participated-in-the-French-Army-s-61st-Artillery-Regiment-Event-FID25-61e-RA-Chaumont.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2508173816","title":"Brookfield Real Assets Income Fund Inc. Announces Quarterly Webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2508173816","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508173816?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:15","pubTimestamp":1738617300,"startTime":"0","endTime":"0","summary":"NEW YORK, Feb. 03, 2025  -- Brookfield Public Securities Group LLC  will host a webcast for Brookfield Real Assets Income Fund Inc.   on Monday, February 10, 2025 at 4:30pm ET. PSG will provide an update on the Fund and on general market conditions.Audio only: +1 323-794-2442 or 800-289-0462Event Code: 924991. It is not necessary to dial into the audio conference, unless you are unable to join via the webcast URL.A fund’s investment objectives, risks, charges and expenses must be considered carefully before investing. The prospectus contains this and other important information about the investment company. Read the prospectus carefully before investing.Quasar Distributors, LLC, provides filing administration for Brookfield Real Assets Income Fund Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/brookfield-real-assets-income-fund-211500957.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RA"],"gpt_icon":0},{"id":"2507392439","title":"Regional SA de Cv (MEX:RA) Q4 2024 Earnings Call Highlights: Strong Loan Growth and Strategic ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2507392439","media":"GuruFocus.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507392439?lang=en_us&edition=fundamental","pubTime":"2025-01-31 15:11","pubTimestamp":1738307470,"startTime":"0","endTime":"0","summary":"Net Income: MXN1,683 million, a 4% year-on-year increase.Return on Average Equity: Increased by 20 basis points year-on-year to 21.3%.Loan Growth: 14% year-on-year, outpacing the banking sector's 12%.Core Deposits: Rose 12% year-on-year compared to the sector's 9% expansion.Financial Margin: Increased by 12% year-on-year and 3% quarter-on-quarter.Efficiency Ratio: 39.7%, a year-on-year reduction of 124 basis points.NPL Ratio: Increased to 1.1% from 0.88% in the previous quarter.Branch Openings: 20 new branches opened in the year.Dividend Distribution: MXN3,000 million in two installments, representing a 46% payout.GuruFocus has detected 2 Warning Signs with MEX:RA.Regional SA de Cv  reported a 4% year-on-year increase in net income for the fourth quarter, reaching MXN1,683 million.Non-financial income saw a notable 20% year-on-year increase, driven by cross-selling strategies.Operating expenses grew 13% year-on-year, primarily due to strategic investments in geographic expansion.Q: Wha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regional-sa-cv-mex-ra-071110781.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RA","RGNLF"],"gpt_icon":0},{"id":"2506373920","title":"Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction","url":"https://stock-news.laohu8.com/highlight/detail?id=2506373920","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506373920?lang=en_us&edition=fundamental","pubTime":"2025-01-27 19:30","pubTimestamp":1737977400,"startTime":"0","endTime":"0","summary":"-- Study met primary endpoint: Enobosarm treatment resulted in statistically significant reduction in the loss of lean mass in subjects receiving WEGOVY (p=0.002) -- -- Patients on Enobosarm on averag","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/27/3015441/11676/en/Veru-Announces-Positive-Topline-Data-from-Phase-2b-QUALITY-Clinical-Study-Enobosarm-Preserved-Lean-Mass-in-Patients-Receiving-WEGOVY-Semaglutide-for-Weight-Reduction.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","VERU","BK4584","BK4557","BK4183"],"gpt_icon":0},{"id":"2504154497","title":"CPF closes Special Accounts for members aged 55 years and above","url":"https://stock-news.laohu8.com/highlight/detail?id=2504154497","media":"Felicia Tan","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504154497?lang=en_us&edition=fundamental","pubTime":"2025-01-19 09:19","pubTimestamp":1737249567,"startTime":"0","endTime":"0","summary":"Members will be notified of their SA closures via physical letters, e-mails and, or SMS from Jan 20.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theedgesingapore.com/news/singapore-news/cpf-closes-special-accounts-members-aged-55-years-and-above?utm_source=Blog&utm_medium=RSS&utm_campaign=Tiger_Brokers_app_RSS","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"edge_highlight","symbols":["RA","BK4211","CPF"],"gpt_icon":0},{"id":"2503302193","title":"Spyre Therapeutics Highlights 2025 Priorities and Robust Pipeline of Upcoming Clinical Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2503302193","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503302193?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:00","pubTimestamp":1736773200,"startTime":"0","endTime":"0","summary":"Phase 1 interim results expected for SPY002, two distinct extended half-life TL1A antibodies, in 2Q2025. Phase 1 interim results expected for SPY003, an extended half-life IL-23 antibody, in 2H2025. Phase 2 platform trial in ulcerative colitis  remains on track for initiation in mid-2025 with SPY001 , followed by SPY002 , SPY003 , and combinations thereof, with initial results expected in 2026. Strong balance sheet with preliminary cash, cash equivalents, and marketable securities balance of over $600M as of December 31, 2024*, anticipated to provide cash runway into the second half of 2028","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/spyre-therapeutics-highlights-2025-priorities-130000578.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IBD","BK4139","SYRE","LENZ","RA"],"gpt_icon":0},{"id":"2503393352","title":"Press Release: Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2503393352","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503393352?lang=en_us&edition=fundamental","pubTime":"2025-01-13 01:00","pubTimestamp":1736701200,"startTime":"0","endTime":"0","summary":"Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results. New biomarkers on track for commercial launch in January 2025. Preliminary financial results indicate record full-year revenue and AVISE CTD trailing twelve-month ASP, with improvements to adjusted EBITDA and cash burn. CARLSBAD, Calif., Jan. 12, 2025  -- Exagen Inc. , a leading provider of autoimmune testing, today announced it has received conditional approval from the New York State Department of Health for its new systemic lupus erythematosus  and rheumatoid arthritis  biomarker assays, with a planned commercial launch in January 2025.  The company also announced preliminary unaudited select financial results for the fourth quarter and full year ended December 31, 2024, in line with prior financial guidance.The company's new SLE and RA biomarkers will be incorporated into the AVISE CTD platform. Collectively, the company expect","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA","LU1894683348.USD","BK4588","IE00B3QW5Z07.USD","SLCT","LU1894683264.USD","IE0034235188.USD","SLE","IE00B64PRP62.GBP","IE00BGHQF748.EUR","R","BK4022","XGN","STT","LU1883839398.USD","BK4585","BK4232","LU0061475181.USD","BK4139","BK4135","BK4077"],"gpt_icon":0},{"id":"2502015228","title":"Press Release: RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2502015228","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502015228?lang=en_us&edition=fundamental","pubTime":"2025-01-09 20:17","pubTimestamp":1736425020,"startTime":"0","endTime":"0","summary":"RheumaGen, Inc. Launches with $15 Million Series A Financing to Advance a New Class of HLA Gene-Editing Therapies for Major Autoimmune Diseases. Company focused on editing the human leukocyte antigen  to transform autoimmunity. Lead program, RG0401, in development for treatment-resistant or refractory rheumatoid arthritis , as a one-time, curative treatment. RheumaGen is developing a breakthrough class of cell and gene therapies designed to cure autoimmune diseases at their source. The company is focused on editing the human leukocyte antigen , or \"immune gene,\" so that the immune system does not attack healthy cells. The company was co-founded by Dr. Brian Freed, the company's Chief Science Officer, who is a professor of medicine and immunology at the University of. \"We are thrilled to have co-led this financing alongside this strong group of experienced investors,\" said Tassos Konstantinou, Managing Director, Life Sciences, at SPRIM Global Investments. \"We are confident in RheumaGen'","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2494935313","title":"Brookfield Real Assets Income Fund Inc. Declares Q1 2025 Distribution Schedule","url":"https://stock-news.laohu8.com/highlight/detail?id=2494935313","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494935313?lang=en_us&edition=fundamental","pubTime":"2024-12-28 05:39","pubTimestamp":1735335540,"startTime":"0","endTime":"0","summary":"NEW YORK, Dec.  27, 2024  (GLOBE NEWSWIRE) -- Brookfield Real Assets Income Fund Inc. (NYSE: RA) (the “Fund”) today announced that its Board of Directors (the “Board”) declared the Fund’s monthly dist","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/27/3002357/0/en/Brookfield-Real-Assets-Income-Fund-Inc-Declares-Q1-2025-Distribution-Schedule.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RA"],"gpt_icon":0},{"id":"2490814225","title":"Press Release: RA Capital Management Announces Close of $1.4 Billion Acquisition of Aliada Therapeutics by AbbVie","url":"https://stock-news.laohu8.com/highlight/detail?id=2490814225","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490814225?lang=en_us&edition=fundamental","pubTime":"2024-12-12 07:23","pubTimestamp":1733959380,"startTime":"0","endTime":"0","summary":"Closing marks second significant acquisition from RA Capital's Raven incubator in 2024, and first acquisition of a company built by Raven from a technology platform in-licensed from a large pharmaceutical company. BOSTON, Dec. 11, 2024 /PRNewswire/ -- RA Capital Management, LP , a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies, today announced that AbbVie has closed its $1.4 billion acquisition of RA Capital's portfolio company Aliada Therapeutics.Aliada's lead investigational asset is ALIA-1758, an anti-pyroglutamate amyloid beta  antibody, which is in development for the treatment of Alzheimer's disease and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a novel blood-brain barrier-crossing technology that enhances delivery of targeted drugs into the central nervous system.Johnson & Johnson , RA Capital, and Raven  co-founded Aliada and co-led the series seed financing i","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509010.AUD","LU1066051225.USD","LU1261432733.SGD","LU1496350502.SGD","LU1989772923.USD","IE0034235303.USD","LU2112291526.USD","SG9999002232.USD","SG9999015978.USD","IE00BVYPNV92.GBP","LU1506573853.SGD","BK4585","LU0985320562.USD","ABBV","LU0792757196.USD","LU0345770308.USD","LU0820561909.HKD","LU1221951046.USD","BK4568","LENZ","LU1914381329.SGD","TM","JNJ","IE00BDGV0183.EUR","LU0795875169.SGD","IE0002141913.USD","LU0708994859.HKD","LU2347655156.SGD","SG9999011175.SGD","IE00BFTCPJ56.SGD","SG9999015945.SGD","LU1929549753.HKD","LU2237443465.HKD","LU0553294199.USD","LU0345769631.USD","IE00B4R5TH58.HKD","RA","LU1496350171.SGD","LU1162221912.USD","LU1430594728.SGD","IE0004445239.USD","LU0545039389.USD","LU0820561818.USD","SG9999003800.SGD","LU1585245621.USD","03160","LU2133065610.SGD","LU1674673428.USD","LU2602419157.SGD","LU0882574055.USD"],"gpt_icon":1},{"id":"2483358945","title":"Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2483358945","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483358945?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:30","pubTimestamp":1731619800,"startTime":"0","endTime":"0","summary":"Significant enhancements will equip clinicians with even more diagnostic clarity in the treatment of patients with autoimmune diseaseCARLSBAD, Calif., Nov.  14, 2024  (GLOBE NEWSWIRE) -- Exagen Inc., ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981652/32920/en/Exagen-Inc-Completes-Validation-and-Regulatory-Submission-for-New-Lupus-and-Rheumatoid-Arthritis-Biomarkers-on-the-AVISE-CTD-Platform.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XGN","BK4139","RA","SLE","BK4077"],"gpt_icon":0},{"id":"2483337470","title":"Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2483337470","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483337470?lang=en_us&edition=fundamental","pubTime":"2024-11-15 05:05","pubTimestamp":1731618300,"startTime":"0","endTime":"0","summary":"NEW YORK and MELBOURNE, Australia, Nov.  14, 2024  (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), (Incannex), a clinical-stage biopharmaceutical company developing innovative medicines f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981582/0/en/Incannex-Healthcare-Inc-Reports-Fiscal-First-Quarter-2025-Financial-Results-and-Business-Updates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AHI","BK4097","HCSG","BK4137","IH","BK4563","CTA","RA","BK4510","BK4167","BK4085"],"gpt_icon":0},{"id":"2483080209","title":"Cullinan Therapeutics Announces Preclinical Data for CLN-978, a CD19-directed T Cell Engager, to be Presented at ACR Convergence 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2483080209","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483080209?lang=en_us&edition=fundamental","pubTime":"2024-11-14 23:01","pubTimestamp":1731596460,"startTime":"0","endTime":"0","summary":"Cullinan will present new in vitro preclinical data that provide further strong rationale for broad clinical development of CLN-978 in autoimmune diseases  Cullinan will share details of global Phase ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/14/2981359/0/en/Cullinan-Therapeutics-Announces-Preclinical-Data-for-CLN-978-a-CD19-directed-T-Cell-Engager-to-be-Presented-at-ACR-Convergence-2024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4110","SLE","BK4077","CGEM","ACR","RA"],"gpt_icon":0},{"id":"2483178806","title":"Poseida Therapeutics Hosts Cell Therapy R&D Day Highlighting Its Innovative Clinical and Preclinical Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2483178806","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483178806?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:00","pubTimestamp":1731592800,"startTime":"0","endTime":"0","summary":"Emerging leadership in allogeneic CAR-T for hematologic malignancies demonstrated by recent P-BCMA-ALLO1 Phase 1 data and new preclinical findings for P-CD19CD20-ALLO1 and P-CD70-ALLO1. Latest preclinical data on P-BCMACD19-ALLO1 demonstrates its potential as a next-generation allogeneic TSCM-rich CAR-T for both autoimmune diseases and oncology. Advancing innovative strategies to overcome the unique challenges of applying CAR-T to solid tumors. SAN DIEGO, Nov. 14, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. , a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, today announced plans to share progress across its clinical- and earlier-stage pipeline of differentiated T stem cell memory cells -rich allogeneic CAR-T therapies in oncology and autoimmune diseases during a virtual R&D Day to be held today at10:00am ET/7:00am PT.The event will feature presentations by mem","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0ZbecZcTygdfn10jwwgw3w--~B/aD0yOTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4f05f1549db26db37f15a45f2f462010"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/poseida-therapeutics-hosts-cell-therapy-140000681.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/poseida-therapeutics-hosts-cell-therapy-140000681.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0225283273.USD","BK4139","LU2357305700.SGD","LU0106261372.USD","LENZ","CAR","BK4230","LU1074936037.SGD","SITC","LU0971096721.USD","BK4581","LU0106831901.USD","BK4127","IE00BZ1G4Q59.USD","BK4080","LU1668664300.SGD","BK4022","BK4588","RA","LU1162221912.USD","IE00BKVL7J92.USD","BK4585","LU1363072403.SGD","PSTX","LU0320765646.SGD","LU1720051108.HKD","BK4534","LU0267386448.USD","LU1548497426.USD","LU1989772840.SGD","SLE","LU0006306889.USD","BK4231","LU0314104364.USD","BK4077","LU1720051017.SGD","LU1989772923.USD","BK4504","LU0098860793.USD","BK4516"],"gpt_icon":0},{"id":"2483503610","title":"OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483503610","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483503610?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:05","pubTimestamp":1731445500,"startTime":"0","endTime":"0","summary":"Conference Call with Slides Begins at 4:30 p.m. Eastern Time Today. EMERYVILLE, Calif., November 12, 2024----OmniAb, Inc.  today reported financial results for the three and nine months ended September 30, 2024, and provided operating and partner program updates.\"We are pleased to report another successful quarter demonstrating our continued commitment to innovation with the expansion of our technology platform and a growing partnership portfolio. Third quarter results reflect consistent growth across key metrics, driven by our planned initiatives and the dedication of our team,\" said Matt Foehr, Chief Executive Officer of OmniAb. \"Our business is well capitalized, and we have a highly scalable model with cutting-edge technologies that are driving significant opportunities. As we move forward, we remain focused on delivering value to our stakeholders and creating sustainable, profitable growth.\". Revenue for the third quarter of 2024 was $4.2 million, compared with $5.5 million for the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/omniab-reports-third-quarter-2024-210500777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4187","GD","BK4566","BK4550","RA","BK4585","OABI","BK4588","BK4121","BK4516","LU0170899867.USD","OABIW"],"gpt_icon":1}],"pageSize":16,"totalPage":4,"pageCount":2,"totalSize":58}]}}